PD-1/CD1a Multi-Domain Molecules for Localized T-Cell Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, particularly atopic dermatitis, often result in undesirable systemic side effects due to systemic therapies, and there is a need for localized treatment strategies that target PD-1 and CD1a to inhibit autoreactive T cells.
Innovation Solution
Development of multi-domain molecules comprising a binding domain for PD-1 and a binding domain for CD1a, with a half-life extending domain, to provide localized inhibition of autoreactive T cells and PD-1 mediated inhibition, using VHH or scFv formats with specific CDR sequences and IgG Fc chains for enhanced stability and targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic therapies are used to treat autoimmune diseases, then therapeutic coverage is improved, but systemic side effects increase
Solution Approach 1:
The patent applies local quality by creating a bispecific molecule that concentrates therapeutic action at the interface between PD-1-expressing T cells and CD1a-expressing antigen-presenting cells. The molecule's dual binding domains enable localized inhibition of T cell activation precisely where autoreactive T cells interact with APCs, rather than systemic suppression throughout the body.
Solution Approach 2:
The therapeutic approach segments the treatment mechanism into two distinct binding functions: one domain targets PD-1 on T cells while the other targets CD1a on APCs. This segmentation allows the single molecule to simultaneously engage both cell types and mediate localized inhibition without requiring systemic immunosuppression.
2Reliability
If PD-1 agonists are used to treat autoimmune diseases, then PD-1 mediated inhibition is achieved, but systemic effects occur
Solution Approach 1:
The bispecific molecule acts as an intermediary that bridges PD-1 on T cells and CD1a on APCs. By requiring simultaneous binding to both targets for full activity, the molecule localizes PD-1 agonist effects to sites of T cell-APC interaction, preventing widespread systemic activation of PD-1 pathways while maintaining effective local inhibition.
3Measurement precision
If localized blockade of autoreactive T cells is implemented by targeting CD1a, then treatment specificity is improved, but therapeutic efficacy may be reduced
Solution Approach 1:
The patent merges two therapeutic mechanisms into a single bispecific molecule: PD-1 agonist activity and CD1a blockade. The PD-1 binding domain provides potent inhibition of T cell activation, while the CD1a binding domain ensures localization to relevant immune synapses. The combination synergistically enhances both specificity and efficacy compared to either mechanism alone.
Data Source
AI summary
The present disclosure provides multi-domain molecules comprising, (i) a first binding domain that binds to PD-1, (ii) a second binding domain that binds to CD1a, and optionally, (iii) a half-life extending domain. Such multi-domain molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as atopic dermatitis (AD).